ストックスクリーナーアプリを入手
18.62
0.48%
-0.09
前日終値:
$18.71
開ける：
$18.4
24時間の取引高:
1.39M
Relative Volume:
0.71
時価総額：
$3.62B
収益：
$1.14B
当期純損益:
$-250.98M
株価収益率:
-13.69
EPS:
-1.36
ネットキャッシュフロー:
$-251.61M
1週間 パフォーマンス:
-0.83%
1か月 パフォーマンス:
-0.11%
6か月 パフォーマンス:
+2.53%
1年 パフォーマンス:
-41.26%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$18.09
$19.25
52週間の値動き範囲:
$16.24
$37.50
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Compare LEGN vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
18.10 | 3.52B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-12 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2026-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2026-07-13 | 再開されました | JP Morgan | Neutral |
| 2026-02-12 | ダウングレード | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-10-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-06-17 | 開始されました | Truist | Buy |
| 2024-05-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-05-23 | 開始されました | Deutsche Bank | Buy |
| 2024-04-17 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | Raymond James | Outperform |
| 2023-12-19 | 開始されました | Scotiabank | Sector Perform |
| 2023-11-06 | 開始されました | Goldman | Buy |
| 2023-05-25 | 開始されました | William Blair | Mkt Perform |
| 2023-05-22 | 開始されました | Daiwa Securities | Buy |
| 2023-03-29 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-11-02 | 開始されました | Evercore ISI | Outperform |
| 2022-11-01 | 開始されました | Cowen | Outperform |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-03-15 | 開始されました | Barclays | Overweight |
| 2022-01-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-07-01 | 開始されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Legend Biotech Corp Adr (LEGN) 最新ニュース
Legend Biotech Director Corazon Sanders Sells 27,370 Shares at $9.46 Average Price - Kalkine Media
Legend Biotech Corporation (LEGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Legend Biotech (NasdaqGS:LEGN) Stock Forecast & Analyst Predictions - Simply Wall Street
Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth? - Yahoo Finance
Data on five-year remission with a myeloma treatment will be presented in Scotland - Stock Titan
Legend Biotech (LEGN) Falls 3.5% to $19.78, Pressing Down on Key Support as CAR-T Sector WeakensVolume Breakout Ideas - https://www.dars.gov.et/
Legend Biotech (LEGN) Falls 3.5% to $19.78, Pressing Down on Key Support as CAR-T Sector WeakensElliott Wave Entry - dars.gov.et
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
H.C. Wainwright reiterates Legend Biotech stock rating at buy - investing.com
Legend Biotech (LEGN) Institutional Ownership 2026 - MarketBeat
Legend Biotech (LEGN) Declines 2.9% as Shares Approach Key $19.65 SupportPassive Flow - siam.in
Legend (LEGN) Quarterly Results: EPS Clears the Reported Estimate at the Close; Latest Reaction: Shares Rise 3.10% for the Current SessionRevenue Warning Signal - dars.gov.et
Legend (LEGN) Quarterly Results: EPS Clears the Reported Estimate at the Close; Latest Reaction: Shares Rise 3.10% for the Current SessionEarnings Momentum Score - dars.gov.et
Legend (LEGN) Quarterly Results: EPS Clears the Reported Estimate at the Close; Latest Reaction: Shares Rise 3.10% for the Current SessionEPS Surprise History - dars.gov.et
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards - Stock Titan
Legend (LEGN) Quarterly Update: EPS Exceeds Its Estimate in Latest Trading; Shares After the Report - dars.gov.et
Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade - MarketBeat
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns - Investing.com
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com South Africa
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com India
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings - MarketBeat
Why is Legend Biotech stock surging today? By Investing.com - Investing.com South Africa
Legend Biotech Q2 2026 slides: first profitable quarter, 50% growth - Investing.com
Legend Biotech Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5% - Investing.com
Why is Legend Biotech stock surging today? - Investing.com
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com South Africa
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com India
Legend Biotech stock rises 5% on earnings and revenue beat - Investing.com
Legend Biotech (NASDAQ:LEGN): What Could Today’s Update Reveal About Cell-Therapy Demand And Manufacturing? - Kalkine Media
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights - Yahoo Finance
Legend Biotech in spotlight: Earnings test Carvykti momentum - Investing.com
1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A. - MarketBeat
LEGN Q1 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Rally 7.6%Retail Earnings Report - careplusvn.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sei Investments Co. Buys 221,899 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
Renaissance Technologies LLC Purchases 119,000 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 315,176 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
H.C. Wainwright reiterates Buy on Legend Biotech stock at $65 - Investing.com
H.C. Wainwright reiterates Buy on Legend Biotech stock, $65 target - Investing.com
Raymond James cuts Legend Biotech stock price target on CEO departure - Investing.com
Why is Legend Biotech stock sliding today? By Investing.com - Investing.com South Africa
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech stock falls as CEO Ying Huang steps down By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down - Investing.com
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim By Investing.com - Investing.com South Africa
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns - Investing.com
Legend Biotech Corp Adr (LEGN) 財務データ
収益
当期純利益
現金流量
EPS
Legend Biotech Corp Adr (LEGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | Director |
Sep 29 '26 |
Proposed Sale |
18.92 |
13,685 |
258,915 |
0 |
| Santos Carlos E | Officer |
Sep 22 '26 |
Proposed Sale |
18.73 |
2,715 |
50,854 |
0 |
| Huang Ying | Former Officer & Director |
Sep 22 '26 |
Proposed Sale |
18.65 |
69,812 |
1,302,109 |
0 |
| Santos Carlos E | Chief Financial Officer |
Sep 21 '26 |
Sale |
9.14 |
5,430 |
49,630 |
14,246 |
| Casey Patrick John | Director |
Jun 30 '26 |
Proposed Sale |
29.60 |
3,000 |
88,800 |
0 |
| Huang Ying | Officer |
Jun 26 '26 |
Proposed Sale |
28.39 |
2,783 |
79,017 |
0 |
| Huang Ying | Chief Executive Officer |
Jun 25 '26 |
Sale |
14.78 |
5,566 |
82,265 |
241,872 |
| Yeung Jessie | Officer |
Mar 26 '26 |
Proposed Sale |
17.54 |
1,862 |
32,663 |
0 |
| Huang Ying | Officer |
Mar 26 '26 |
Proposed Sale |
17.54 |
4,968 |
87,149 |
0 |
| Huang Ying | Chief Executive Officer |
Mar 25 '26 |
Sale |
8.77 |
9,936 |
87,139 |
247,438 |
2.81%
大文字化:
|
ボリューム (24 時間):